Citigroup’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-41,476
| Closed | -$788K | – | 8003 |
|
|
2019
Q1 | $788K | Buy |
+41,476
| New | +$673K | ﹤0.01% | 3673 |
|
|
2017
Q1 | – | Sell |
-20,007
| Closed | -$98K | – | 7560 |
|
|
2016
Q4 | $98K | Sell |
20,007
-2,270
| -10% | -$11.6K | ﹤0.01% | 5789 |
|
|
2016
Q3 | $110K | Buy |
22,277
+10,661
| +92% | +$54.6K | ﹤0.01% | 5142 |
|
|
2016
Q2 | $59K | Sell |
11,616
-8,399
| -42% | -$45.2K | ﹤0.01% | 5477 |
|
|
2016
Q1 | $114K | Buy |
20,015
+6,665
| +50% | +$46.5K | ﹤0.01% | 5577 |
|
|
2015
Q4 | $138K | Buy |
13,350
+9,849
| +281% | +$134K | ﹤0.01% | 5076 |
|
|
2015
Q3 | $65K | Sell |
3,501
-5,503
| -61% | -$106K | ﹤0.01% | 5263 |
|
|
2015
Q2 | $175K | Buy |
9,004
+3,476
| +63% | +$61.5K | ﹤0.01% | 4539 |
|
|
2015
Q1 | $98K | Sell |
5,528
-13,045
| -70% | -$219K | ﹤0.01% | 5044 |
|
|
2014
Q4 | $297K | Buy |
18,573
+7,990
| +75% | +$107K | ﹤0.01% | 4367 |
|
|
2014
Q3 | $133K | Sell |
10,583
-377
| -3% | -$5.38K | ﹤0.01% | 4527 |
|
|
2014
Q2 | $171K | Sell |
10,960
-11,579
| -51% | -$170K | ﹤0.01% | 4263 |
|
|
2014
Q1 | $296K | Buy |
22,539
+4,014
| +22% | +$62.8K | ﹤0.01% | 3964 |
|
|
2013
Q4 | $298K | Buy |
18,525
+9,098
| +97% | +$145K | ﹤0.01% | 4285 |
|
|
2013
Q3 | $158K | Buy |
9,427
+9,237
| +4,862% | +$137K | ﹤0.01% | 4365 |
|
|
2013
Q2 | $2K | Buy |
+190
| New | +$2K | ﹤0.01% | 6592 |
|
Other funds holding OSIR
Citigroup's OSIR Position: Q2 2019 in Review
Citigroup sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 41,476 shares — an estimated $788K sold.
Citigroup first reported a position in OSIR in Q2 2013 and held it in 16 quarters. The position peaked at $788K in Q1 2019. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.
- Citigroup reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
- Citigroup sold 41,476 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $788K.
- Citigroup first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 16 quarters.
- Citigroup's Osiris Therapeutics, Inc. Common Stock position peaked at $788K in Q1 2019.
- 1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.
Based on Citigroup's 13F filing for Q2 2019, filed 12 Aug 2019.